Agilent Technologies said on Monday that it will acquire privately held clinical pathology company Biocare Medical in an all-cash deal valued at $950 million.
Agilent announced that it will purchase the California-based Biocare Medical from investment firms Excellere Partners and GHO Capital Partners, with the transaction expected to close by the fourth fiscal quarter of 2026.
Biocare Medical offers a range of integrated tissue diagnostic products used in the detection of cancer and infectious diseases, and its website lists government and military laboratories among its clients.
Agilent Technologies, which has a market capitalization of about $33.38 billion according to London Stock Exchange Group (LSEG) data, reported first-quarter results in February that largely matched analysts’ expectations, indicating steady demand for its medical instruments and other laboratory equipment.
About Agilent Technologies
Agilent Technologies is a global company based in Santa Clara that focuses on life sciences, diagnostics, and chemical analysis markets. The company was founded in 1999 after being spun off from Hewlett-Packard. Agilent develops and supplies a wide range of laboratory products, including scientific instruments, software, services, and consumables used in research and testing laboratories. These tools help scientists with activities such as medical research, drug discovery, and diagnostic testing. The company also supports efforts to improve health and safety by providing technologies that help test the quality of food, water, and air. Agilent’s advanced analytical solutions including technologies like chromatography and mass spectrometry, are widely used by laboratories in pharmaceutical, clinical, environmental, and academic sectors around the world.
